Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New Elite Feature:   Find Similar Charts in Seconds

Learn How
Market News Market Pulse Stocks News ETF News Crypto News

uniQure Inc.

Contributing Author

Recent Articles by uniQure Inc.

Sep-29
uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington's Disease Showing Continued Slowing of Disease Progression QURE -37.33% GlobeNewswire
Sep-02
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington's Disease QURE GlobeNewswire
Jul-29
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update QURE +9.30% GlobeNewswire
Jul-22
uniQure to Announce Second Quarter 2026 Financial Results QURE GlobeNewswire
Jun-25
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares QURE GlobeNewswire
Jun-23
uniQure Announces Pricing of Upsized $225 Million Public Offering QURE GlobeNewswire
Jun-22
uniQure Announces $150 Million Proposed Public Offering QURE GlobeNewswire
Jun-19
uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy QURE GlobeNewswire
Jun-17
uniQure Announces Plan for BLA Submission for AMT-130 in Huntington's Disease QURE +78.44% GlobeNewswire
May-05
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates QURE GlobeNewswire
Apr-30
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease QURE +19.25% GlobeNewswire
Apr-28
uniQure to Announce First Quarter 2026 Financial Results QURE GlobeNewswire
Mar-02
uniQure Announces 2025 Financial Results and Provides Recent Company Updates QURE -32.82% GlobeNewswire
Mar-02
uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease QURE -32.82% GlobeNewswire
Feb-23
uniQure to Announce 2025 Financial Results QURE GlobeNewswire
Feb-06
uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in a-Gal A Enzyme Activity in Patients with Fabry Disease QURE GlobeNewswire
Jan-09
uniQure Announces Type A Meeting Scheduled with FDA QURE +9.37% GlobeNewswire
Dec-04
uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease QURE -10.75% GlobeNewswire
Nov-10
uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update QURE -5.90% GlobeNewswire
Nov-06
uniQure to Announce Third Quarter 2025 Financial Results QURE +5.56% GlobeNewswire
Nov-03
uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease QURE -49.34% GlobeNewswire
Sep-29
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares QURE +9.37% GlobeNewswire
Sep-25
uniQure Announces Pricing of Upsized $300 Million Public Offering QURE GlobeNewswire
Sep-24
uniQure Announces $200 Million Proposed Public Offering QURE +247.73% GlobeNewswire
Sep-24
uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding QURE +247.73% GlobeNewswire
Sep-24
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington's Disease QURE +247.73% GlobeNewswire
Sep-05
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in a-Gal A Enzyme Activity in Patients with Fabry Disease QURE GlobeNewswire
Jul-29
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress QURE -8.68% GlobeNewswire
Jul-22
uniQure to Announce Second Quarter 2025 Financial Results QURE GlobeNewswire
Jun-11
uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer QURE GlobeNewswire
Jun-02
uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease QURE GlobeNewswire
May-29
uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE) QURE GlobeNewswire
May-09
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress QURE GlobeNewswire
May-05
uniQure to Announce First Quarter 2025 Financial Results QURE +7.58% QURE -27.75% GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)